World Health Organization (WHO). Coronavirus (2021). Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1.

Indonesian Thalassemia Foundation. Report on The Number of People Living with Thalassemia in Indonesia. Jakarta; 2021 (unpublished report).

Atmakusuma D, Eleftheriou A, Skafi A, Loriz Brunetta A. Meet the experts: COVID-19 vaccines for thalassemia survivors: do's and don'ts. In: Thalassaemia International Federation Publications, 2021. Available at: https://thalassaemia.org.cy/it/publications/tif-publications/

De Sanctis V, Canatan D, Corrons JLV, et al. A comprehensive update of ICET-A network on COVID-19 in thalassemias: what we know and where we stand. Acta Biomed. 2020;91:e2020026.

Lansiaux E, Pebay PP, Picard JL, Son-Forget J. COVID-19: beta-thalassemia subjects immunised? Med Hypotheses. 2020;142:109827.

Papadopoulos KI, Sutheesophon W, Manipalviratn S, Aw TC. A South-East Asian perspective on the COVID-19 pandemic: hemoglobin E - trait confers resistance against COVID-19. Med Sci Monit Basic Res. 2021;27:e929207.

Weatherall DJ, Clegg JB. The thalassaemia syndromes. Blackwell Science Ltd, Hoboken, USA, 2001: 846 pp.

Marhaeni W, Wijaya AB, Kusumaningtyas P, Mapianto RS. Thalassemic child presenting with anosmia due to COVID-19. Indian J Pediatr. 2020;87:750.

Liu W, L H. COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74fa50f50db305139743d

Torti L, Maffei L, Sorrentino F, et al. Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects? Mediterr J Hematol Infect Dis. 2020;12:e2020052.

Farmakis D, Giakoumis A, Polymeropoulo E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit. 2003;9:19-22.

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-1. Journal of Infection. 2020;80:607-613.

Okar L, Ali M, Parengal J, Yassin MA. COVID-19 and thalassemia beta major in splenectomized patient: clinical case progression and literature review. Clin Case Rep. 2020;8:2918-2922.

Chowdhury SF, Anwar S. Management of hemoglobin disorders during the COVID-19 pandemic. Front Med (Lausanne). 2020;7:306.

Karimi M, De Sanctis V. Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the "high clinical risk" category? Acta Biomed. 2020;91:50-56.

Eleftheriou A, Cannon L, Angastiniotis M. Thalassemia prior and consequent to COVID-19 pandemic. The perspective of Thalassemia International Federation. Thalassemia Reports. 2020;10.

CSIS. South-East Asia COVID-19 Tracker. Available at: https://www.csis.org/programs/southeast-asia-program/projects/southeast-asia-covid-19-tracker.